Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Branched Chain Amino Acids: Beyond Nutrition Metabolism

(2018) Cunxi Nie et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

1H NMR metabolic profiling of gastric cancer patients with lymph node metastasis

(2018) Hailong Zhang et al.   Metabolomics

Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis

(2018) Guo-Li Shao et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

Basal-like Breast Cancers: From Pathology to Biology and Back Again

(2018) Barry Gusterson et al.   Stem Cell Reports

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation

(2017) Simon Raffel et al.   NATURE

The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer

(2017) V Thewes et al.   ONCOGENE

BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases

(2017) Adonia E. Papathanassiu et al.   Nature Communications

DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines

(2016) Dulamsuren Oktyabri et al.   BIOCHIMIE

BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin

(2016) Yi-Hu Zheng et al.   LIVER INTERNATIONAL

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Comparison of immunoreactive score, HER2/neuscore and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms

(2015) Elisa Specht et al.   HISTOPATHOLOGY

Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer

(2015) Sung Jeep Kim et al.   Journal of Breast Cancer

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events

(2014) Carolin Bock et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy

(2013) Rosa Nadal et al.   INTERNATIONAL JOURNAL OF CANCER

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness

(2013) Federica Brugnoli et al.   Molecular Cancer

BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1

(2013) Martje Tönjes et al.   NATURE MEDICINE

Semi-quantitative immunohistochemical assay versus oncotype DX® qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study

(2012) James A Kraus et al.   MODERN PATHOLOGY

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

(2011) Makiko Ono et al.   BREAST CANCER RESEARCH AND TREATMENT

Treatment of triple negative breast cancer (TNBC): current options and future perspectives

(2010) M. De Laurentiis et al.   CANCER TREATMENT REVIEWS

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

(2010) Sunil Badve et al.   MODERN PATHOLOGY

Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks

(2010) Kouichi Tabu et al.   Molecular Cancer

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

Triple-negative breast cancer: Novel therapies and new directions

(2009) Sumanta Kumar Pal et al.   MATURITAS

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive

(2008) Ben Van Calster et al.   BREAST CANCER RESEARCH AND TREATMENT

Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients

(2008) F. Zeppernick et al.   CLINICAL CANCER RESEARCH

Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy

(2008) Paul L. Nguyen et al.   JOURNAL OF CLINICAL ONCOLOGY